Second person dies in anti-obesity drug trial

A second patient has died in a late-stage trial of the anti-obesity drug beloranib, according to a report in PharmaTimes.

The drug, developed by US biotech Zafgen for the genetic disorder Prader-Willi syndrome, has a chequered history.

US regulators suspended

Latest

Trending